Agenus reports Q1 EPS ($1.03), consensus ($1.98)

Reports Q1 revenue $24.066M, consensus $21.98M. “The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and fuels our unwavering commitment to delivering this combination to patients,” said Garo Armen, Ph.D., Chairman and CEO of Agenus (AGEN). “With expanded datasets, key leadership appointments, and the FDA’s renewed focus on accelerating cures and meaningful treatments, Agenus is entering a pivotal phase-advancing toward regulatory engagement with financial discipline and a sharp focus on bringing innovative immunotherapies to individuals living with cancer.”